{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:12Z","timestamp":1787020092687,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors, benzodiazepines, and antipsychotics are considered potentially inappropriate medications in older adults according to the American Geriatric Society Beers Criteria, and deprescribing algorithms have been developed to guide use of these drug classes. The objective of this study was to describe the number of beneficiaries prescribed these medications, provider specialty and regional trends in prescribing, and the aggregate costs for these claims in Medicare Part D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cross-sectional study using publicly available Medicare Provider Utilization and Payment Data: Part D Prescriber data for years 2013\u20132019. Descriptive statistics and the Cochrane-Armitage test were used to summarize the trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 30.1%, 25.6%, 4.6% of Medicare Part D beneficiaries had a proton pump inhibitor, benzodiazepine, and antipsychotic claim in 2013, respectively. These rates decreased to 27.5%, 17.5%, 4.1% in 2019 (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.0001). However, the number of standardized 30-day claims increased from 63 million in 2013 to 84 million in 2019 for proton pump inhibitors, remained steady for benzodiazepines and slightly increased (10 million to 13 million) for antipsychotics. Total aggregate costs decreased by almost $1.5 billion for proton pump inhibitor, $100 million for benzodiazepine, and $700 million for antipsychotic from 2013 to 2019 (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.0001). Almost 93% of gastroenterologists prescribed a proton pump inhibitor, and 60% of psychiatrists prescribed benzodiazepines and antipsychotics all seven years. The Other region had the highest percentage of providers prescribing all three classes and the highest number of standardized 30-day benzodiazepine claims.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The overall rate of use of proton pump inhibitors, benzodiazepines, and antipsychotics decreased from 2013\u20132019 among Medicare Part D beneficiaries. Despite the increase in raw number of standardized 30-day claims, the costs decreased which is likely due to generics made available. These prescribing trends may aid in identifying and targeting potential deprescribing interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-022-02971-2","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T19:03:21Z","timestamp":1649444601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers"],"prefix":"10.1186","volume":"22","author":[{"given":"Jennifer M.","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manvi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"2971_CR1","doi-asserted-by":"publisher","unstructured":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","DOI":"10.1111\/jgs.15767"},{"issue":"5","key":"2971_CR2","first-page":"354","volume":"63","author":"B Farrell","year":"2017","unstructured":"Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354\u201364.","journal-title":"Can Fam Physician"},{"issue":"1","key":"2971_CR3","first-page":"17","volume":"64","author":"LM Bjerre","year":"2018","unstructured":"Bjerre LM, Farrell B, Hogel M, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17\u201327.","journal-title":"Can Fam Physician"},{"issue":"5","key":"2971_CR4","first-page":"339","volume":"64","author":"K Pottie","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339\u201351.","journal-title":"Can Fam Physician"},{"issue":"5","key":"2971_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827\u201334. https:\/\/doi.org\/10.1001\/jamainternmed.2015.0324.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2971_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11894-019-0732-3","volume":"21","author":"T Kanno","year":"2019","unstructured":"Kanno T, Moayyedi P. Proton pump inhibitors in the elderly, balancing risk and benefit: an age-old problem. Curr Gastroenterol Rep. 2019;21(12):65. https:\/\/doi.org\/10.1007\/s11894-019-0732-3.","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"2971_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0828","volume":"2","author":"I Yunusa","year":"2019","unstructured":"Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia. JAMA Netw Open. 2019;2(3): e190828. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0828.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2971_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.18553\/jmcp.2015.21.7.585","volume":"21","author":"BJ Zarowitz","year":"2015","unstructured":"Zarowitz BJ, Allen C, O\u2019Shea T, Strauss ME. Risk factors, clinical characteristics, and treatment differences between residents with and without nursing home- and non-nursing home-acquired clostridium difficile infection. J Manag Care Spec Pharm. 2015;21(7):585\u201395. https:\/\/doi.org\/10.18553\/jmcp.2015.21.7.585.","journal-title":"J Manag Care Spec Pharm"},{"key":"2971_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eclinm.2019.02.001","volume":"8","author":"IM Zacharioudakis","year":"2019","unstructured":"Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E. Association of community factors with hospital-onset Clostridioides (Clostridium) difficile infection: a population based U.S.-wide study. EClinicalMedicine. 2019;8:12\u20139. https:\/\/doi.org\/10.1016\/j.eclinm.2019.02.001.","journal-title":"EClinicalMedicine."},{"issue":"11","key":"2971_CR10","doi-asserted-by":"publisher","first-page":"e1915348","DOI":"10.1001\/jamanetworkopen.2019.15348","volume":"2","author":"RT Emeny","year":"2019","unstructured":"Emeny RT, Chang CH, Skinner J, et al. Association of receiving multiple, concurrent fracture-associated drugs with hip fracture risk. JAMA Netw Open. 2019;2(11):e1915348. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.15348.","journal-title":"JAMA Netw Open."},{"issue":"12","key":"2971_CR11","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00198-018-4697-0","volume":"29","author":"JC Munson","year":"2018","unstructured":"Munson JC, Bynum JP, Bell JE, et al. Impact of prescription drugs on second fragility fractures among US medicare patients. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2018;29(12):2771\u20139. https:\/\/doi.org\/10.1007\/s00198-018-4697-0.","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"issue":"6","key":"2971_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-014-9855-6","volume":"94","author":"J Ding","year":"2014","unstructured":"Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int. 2014;94(6):597\u2013607. https:\/\/doi.org\/10.1007\/s00223-014-9855-6.","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2971_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/archinternmed.2010.34","volume":"170","author":"KM Stockl","year":"2010","unstructured":"Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704\u201310. https:\/\/doi.org\/10.1001\/archinternmed.2010.34.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2971_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/gutjnl-2020-322248","volume":"70","author":"SW Lee","year":"2021","unstructured":"Lee SW, Ha EK, Yeniova A\u00d6, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70(1):76\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2020-322248.","journal-title":"Gut"},{"issue":"6","key":"2971_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/MOG.0000000000000676","volume":"36","author":"ML Schubert","year":"2020","unstructured":"Schubert ML. Proton pump inhibitors: misconceptions and proper prescribing practice. Curr Opin Gastroenterol. 2020;36(6):493\u2013500. https:\/\/doi.org\/10.1097\/MOG.0000000000000676.","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"2971_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2036.2008.03706.x","volume":"28","author":"NS Abraham","year":"2008","unstructured":"Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2008;28(1):97\u2013106. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03706.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2971_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.cgh.2010.01.002","volume":"8","author":"NS Abraham","year":"2010","unstructured":"Abraham NS, Hartman C, Hasche J. Reduced hospitalization cost for upper gastrointestinal events that occur among elderly veterans who are gastroprotected. Clin Gastroenterol Hepatol. 2010;8(4):350\u20136. https:\/\/doi.org\/10.1016\/j.cgh.2010.01.002.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"2971_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton-pump-inhibitor co-therapy with hospitalization for upper gastrointestinal bleeding. JAMA. 2018;320(21):2221\u201330. https:\/\/doi.org\/10.1001\/jama.2018.17242.","journal-title":"JAMA"},{"issue":"6","key":"2971_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1053\/j.gastro.2016.08.054","volume":"151","author":"WA Ray","year":"2016","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105-1112.e10. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.054.","journal-title":"Gastroenterology"},{"issue":"9","key":"2971_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","volume":"169","author":"M Steinberg","year":"2012","unstructured":"Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12030342.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2971_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/jgs.14076","volume":"64","author":"KJ Neufeld","year":"2016","unstructured":"Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotics for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705\u201314. https:\/\/doi.org\/10.1111\/jgs.14076.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2971_CR22","doi-asserted-by":"publisher","first-page":"371.e11","DOI":"10.1016\/j.jamda.2017.12.098","volume":"19","author":"LJ Seppala","year":"2018","unstructured":"Seppala LJ, Wermelink AMAT, de Vries M, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics J Am Med Dir Assoc. 2018;19(4):371.e11-371.e17. https:\/\/doi.org\/10.1016\/j.jamda.2017.12.098.","journal-title":"Psychotropics J Am Med Dir Assoc"},{"issue":"11","key":"2971_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91(11):1632\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2016.07.024.","journal-title":"Mayo Clin Proc"},{"key":"2971_CR24","doi-asserted-by":"publisher","unstructured":"Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand Name and Generic Proton Pump Inhibitor Prescriptions in the United States: Insights from the National Ambulatory Medical Care Survey (2006\u20132010). Gastroenterol Res Pract. 2015;2015. Article ID 689531, 7 pages. https:\/\/doi.org\/10.1155\/2015\/689531","DOI":"10.1155\/2015\/689531"},{"issue":"7\u20138","key":"2971_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1345\/aph.1G703","volume":"40","author":"CQ Pham","year":"2006","unstructured":"Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother. 2006;40(7\u20138):1261\u20136. https:\/\/doi.org\/10.1345\/aph.1G703.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"2971_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/SMJ.0b013e31828db01f","volume":"106","author":"F Leri","year":"2013","unstructured":"Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106(4):270\u20133. https:\/\/doi.org\/10.1097\/SMJ.0b013e31828db01f.","journal-title":"South Med J"},{"issue":"2","key":"2971_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.18553\/jmcp.2010.16.2.122","volume":"16","author":"L Thomas","year":"2010","unstructured":"Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122\u20139. https:\/\/doi.org\/10.18553\/jmcp.2010.16.2.122.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"2971_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/WAD.0000000000000336","volume":"33","author":"KE Lind","year":"2019","unstructured":"Lind KE, Raban MZ, Georgiou A, Westbrook JI. Duration of antipsychotic medication use by aged care facility residents with dementia. Alzheimer Dis Assoc Disord. 2019;33(4):331\u20138. https:\/\/doi.org\/10.1097\/WAD.0000000000000336.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"2","key":"2971_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136\u201342.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"2971_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.sleep.2011.12.014","volume":"13","author":"CI Neutel","year":"2012","unstructured":"Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. Sleep Med. 2012;13(7):893\u20137. https:\/\/doi.org\/10.1016\/j.sleep.2011.12.014.","journal-title":"Sleep Med"},{"key":"2971_CR31","unstructured":"Medicare Provider Utilization and Payment Data: Part D Prescriber | CMS. Updated December 1, 2021. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Part-D-Prescriber. Accessed 4 Apr 2022."},{"key":"2971_CR32","unstructured":"The Centers for Medicare & Medicaid Services, Office of Enterprise Data and Analytics. Medicare Fee-For Service Provider Utilization & Payment Data Part D Prescriber Public Use File: A Methodological Overview. Published online November 6, 2020. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Downloads\/Prescriber_Methods.pdf. Accessed 4 Mar 2022."},{"key":"2971_CR33","unstructured":"Medicare Part D Prescribers - by Provider and Drug Data Dictionary - Centers for Medicare & Medicaid Services Data. Updated August 25, 2021. https:\/\/data.cms.gov\/resources\/medicare-part-d-prescribers-by-provider-and-drug-data-dictionary. Accessed 4 Mar 2022."},{"key":"2971_CR34","unstructured":"US Census Bureau. 2010 Census Regions and Divisions of the United States. Census.gov. Updated October 8, 2021. https:\/\/www.census.gov\/geographies\/reference-maps\/2010\/geo\/2010-census-regions-and-divisions-of-the-united-states.html. Accessed 4 Mar 2022."},{"issue":"2","key":"2971_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.sapharm.2016.02.012","volume":"13","author":"PP Rane","year":"2017","unstructured":"Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Soc Adm Pharm. 2017;13(2):358\u201363. https:\/\/doi.org\/10.1016\/j.sapharm.2016.02.012.","journal-title":"Res Soc Adm Pharm"},{"issue":"2","key":"2971_CR36","doi-asserted-by":"publisher","first-page":"w305","DOI":"10.1377\/hlthaff.28.2.w305","volume":"28","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Patrick AR, Pedan A, et al. The effect of medicare part d coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff Proj Hope. 2009;28(2):w305\u201316. https:\/\/doi.org\/10.1377\/hlthaff.28.2.w305.","journal-title":"Health Aff Proj Hope"},{"issue":"12","key":"2971_CR37","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/j.1532-5415.2008.02025.x","volume":"56","author":"WH Shrank","year":"2008","unstructured":"Shrank WH, Patrick AR, Pedan A, et al. The effect of transitioning to medicare part d drug coverage in seniors dually eligible for medicare and medicaid. J Am Geriatr Soc. 2008;56(12):2304\u201310. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.02025.x.","journal-title":"J Am Geriatr Soc"},{"key":"2971_CR38","unstructured":"Gray N. Teva wins big as FDA approves its generic Nexium. BioPharma Dive. Published January 27, 2015. Accessed July 16, 2020. https:\/\/www.biopharmadive.com\/news\/teva-wins-big-as-fda-approves-its-generic-nexium\/357098\/"},{"key":"2971_CR39","unstructured":"New Drug Application (NDA): 204655. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=204655. Accessed 17 Feb 2021."},{"key":"2971_CR40","unstructured":"2017 First Generic Drug Approvals. FDA. Updated February 20, 2018. https:\/\/www.fda.gov\/drugs\/first-generic-drug-approvals\/2017-first-generic-drug-approvals. Accessed 16 July 2020."},{"issue":"1","key":"2971_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27\u201337. https:\/\/doi.org\/10.5009\/gnl15502.","journal-title":"Gut Liver"},{"issue":"2","key":"2971_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/lary.27916","volume":"130","author":"FS Luetzenberg","year":"2020","unstructured":"Luetzenberg FS, Jiang N. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties. Laryngoscope. 2020;130(2):321\u20137. https:\/\/doi.org\/10.1002\/lary.27916.","journal-title":"Laryngoscope"},{"issue":"1","key":"2971_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1590\/2237-6089-2019-0015","volume":"42","author":"K Pan","year":"2020","unstructured":"Pan K, Silver S, Davis C, Pan K, Silver S, Davis C. Analysis of psychiatrists\u2019 prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States. Trends Psychiatry Psychother. 2020;42(1):48\u201354. https:\/\/doi.org\/10.1590\/2237-6089-2019-0015.","journal-title":"Trends Psychiatry Psychother"},{"issue":"4","key":"2971_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","volume":"60","author":"CM Campanelli","year":"2012","unstructured":"Campanelli CM. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616\u201331. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.03923.x.","journal-title":"J Am Geriatr Soc"},{"key":"2971_CR45","doi-asserted-by":"publisher","unstructured":"Gray E, Bradley B. Evaluation of the prescribing practices of nonbenzodiazepine, benzodiazepine receptor agonist hypnotics in adults at a federally qualified health center. J Am Pharm Assoc (2003). 2019;59(4S):S146\u201350. https:\/\/doi.org\/10.1016\/j.japh.2019.05.006.","DOI":"10.1016\/j.japh.2019.05.006"},{"key":"2971_CR46","unstructured":"FDA approves first generic Abilify. Formulary Watch. 2015. https:\/\/www.formularywatch.com\/view\/fda-approves-first-generic-abilify. Accessed 19 Feb 2021."},{"key":"2971_CR47","unstructured":"Intellipharmaceutics International Inc. Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR\u00ae. GlobeNewswire News Room. Published October 7, 2016. http:\/\/www.globenewswire.com\/news-release\/2016\/10\/07\/878050\/0\/en\/Intellipharmaceutics-Announces-FDA-Tentative-Approval-for-Generic-Seroquel-XR.html. Accessed 19 Feb 2021."},{"issue":"10","key":"2971_CR48","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1176\/ps.2008.59.10.1191","volume":"59","author":"H Chen","year":"2008","unstructured":"Chen H, Nwangwu A, Aparasu R, Essien E, Sun S, Lee K. The impact of medicare part d on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008;59(10):1191\u20137. https:\/\/doi.org\/10.1176\/ps.2008.59.10.1191.","journal-title":"Psychiatr Serv"},{"issue":"8","key":"2971_CR49","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1177\/1060028018759747","volume":"52","author":"O Avraham","year":"2018","unstructured":"Avraham O, Biglow M. Implementation of proton pump inhibitor deprescription protocol in geriatric residents. Ann Pharmacother. 2018;52(8):747\u201353. https:\/\/doi.org\/10.1177\/1060028018759747.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2971_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.japh.2019.08.012","volume":"60","author":"DR Odenthal","year":"2020","unstructured":"Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc. 2020;60(1):100\u20134. https:\/\/doi.org\/10.1016\/j.japh.2019.08.012.","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"2971_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40266-017-0442-1","volume":"34","author":"TD Wilsdon","year":"2017","unstructured":"Wilsdon TD, Hendrix I, Thynne TRJ, Mangoni AA. Effectiveness of interventions to deprescribe inappropriate proton pump inhibitors in older adults. Drugs Aging. 2017;34(4):265\u201387. https:\/\/doi.org\/10.1007\/s40266-017-0442-1.","journal-title":"Drugs Aging"},{"issue":"1","key":"2971_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5770\/cgj.23.419","volume":"23","author":"DK Conn","year":"2020","unstructured":"Conn DK, Hogan DB, Amdam L, et al. Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults. Can Geriatr J. 2020;23(1):116\u201322. https:\/\/doi.org\/10.5770\/cgj.23.419.","journal-title":"Can Geriatr J"},{"issue":"6","key":"2971_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1192\/bjp.bp.113.134650","volume":"204","author":"C Vicens","year":"2014","unstructured":"Vicens C, Bejarano F, Sempere E, et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014;204(6):471\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.113.134650.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2971_CR54","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","volume":"174","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890. https:\/\/doi.org\/10.1001\/jamainternmed.2014.949.","journal-title":"JAMA Intern Med"},{"issue":"3\u20134","key":"2971_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000355418","volume":"37","author":"YJ Pan","year":"2014","unstructured":"Pan YJ, Wu CS, Gau SSF, Chan HY, Banerjee S. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled Studies. Dement Geriatr Cogn Disord. 2014;37(3\u20134):125\u201340. https:\/\/doi.org\/10.1159\/000355418.","journal-title":"Dement Geriatr Cogn Disord"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-02971-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-022-02971-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-02971-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T19:03:54Z","timestamp":1649444634000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-022-02971-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2971"],"URL":"https:\/\/doi.org\/10.1186\/s12877-022-02971-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study has been determined as exempt by the University of Mississippi Institution Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HMH is funded by Healthcare Services Corporation, a foundation of Blue Cross\/Blue Shield, for a study of deprescribing. There is no relationship between the funding and this manuscript under consideration. MS is funded by Handa Oncology, for a study of drug-drug interactions. There is no relationship between the funding and this manuscript under consideration. JMT was formerly a consultant for Takeda Pharmaceutical Company, which is unrelated to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}